US panel to review Lilly/Daiichi's prasugrel in February
This article was originally published in Scrip
The US FDA's cardiovascular and renal drugs advisory panel will meet on February 3rd to review Lilly/Daiichi Sankyo's Effient (prasugrel), further delaying US approval of the novel platelet inhibitor. The NDA was filed in December 2007 and designated for priority review. In June the FDA extended the review period by three months, later allowing the re-set September deadline to pass without action. The panel will be asked to weigh prasugrel's risks and benefits in light of results from the pivotal TRITON-TIMI 38 study, in which the drug provided a 19% reduction in major cardiovascular events compared with Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in acute coronary syndrome patients undergoing percutaneous coronary intervention, albeit with a 32% increase in serious bleeding. In December the EU's CHMP granted a positive opinion recommending approval of prasugrel (as Efient).
You may also be interested in...
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.